drugset / Trial / NCT01485588
Safety and Tolerability Study for Age-Related Macular Degeneration
Non-randomizedSequentialOpen-labelTreatment
Summary
Phase 1: The purpose of this study is to evaluate the safety and tolerability of single ascending doses of hI-con1™ for subjects with Age-Related Macular Degeneration. Phase 2: The purpose of this study is to evaluate the safety of 3 injections of hI-con1™ at 2 different dose levels.
Timeline
- Start
- 2010-12
- Primary completion
- 2012-03
- Completion
- 2012-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | hI-con1 | Unknown | 0.06 ml | Intravitreal |
| Subject | hI-con1 | Unknown | 0.15 ml | Intravitreal |
| Subject | hI-con1 | Unknown | 0.3 ml | Intravitreal |